Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mark Ratner

Set Alert for Articles By Mark Ratner

Latest From Mark Ratner

Science Matters: A Druggable Target For PTEN-Deficient Prostate Cancer

By taking a different slant on synthetic lethality – the therapeutic process behind AstraZeneca's Lynparza –scientists have identified a potential new drug target for use in prostate cancer, the chromatin helicase DNA-binding factor CHD1.

Research and Development Strategies Cancer

Diagnostics In 2016: From Alere To Zika

No significant trends emerged in diagnostics M&A or financing this past year, which did see the introduction of several government-funded initiatives, elements of which will bolster diagnostics innovation. As in other sectors of health care, the biggest question is how the incoming Trump administration could change US regulatory and funding policies.

Analysis Innovation

Science Matters: Insights Into Gut-Brain Signaling Raise Hopes For Treating Neurological Disorders

New research offers mechanistic proof of signaling between gut and brain in Parkinson’s disease, showing that introducing an altered microbiome from PD patients into a mouse model can recreate the motor symptoms of the disease.

Neurology Innovation

Science Matters: Innovative Strategy Identifies New Antibiotic Class From The Microbiome

New research lays out both method and proof of principle for a strategy that combines bioinformatics and synthetic chemistry to enable more expansive development of antibiotics and other drugs derived from natural products.

Research & Development Infectious Diseases

How Immuno-Oncology Is Turning Biomarker Development On Its Head

Immuno-oncology’s challenge is to orchestrate a biomarker program in a highly competitive drug development landscape knowing that prior to having significant clinical experience, the program is unlikely to yield the kinds of binary measurements used to define and select a patient population for a targeted therapy.

Personalized Medicine Research and Development Strategies

A Lesson From Tecentriq’s Development

Roche chose not to limit enrollment to patients with high levels of PD-L1 expression when it moved Tecentriq into Phase II – unlike Merck, which did not include low PD-L1 expressers in its Keytruda lung cancer trials.

BioPharmaceutical Personalized Medicine
See All